Gene therapy start-up VectorY and Wageningen University sign strategic collaboration
Two-part project to develop novel baculovirus genome seeds and bioprocess technologies for the scalable production of AAV gene therapies
27-Jan-2022 -
VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, announces a collaboration with Wageningen University to develop novel baculovirus-based ...
baculovirus
bioprocessing
gene therapy